Literature DB >> 12543722

Lymphatic vessel activation in cancer.

Melanie Cassella1, Mihaela Skobe.   

Abstract

Metastasis of most cancers occurs primarily through the lymphatic system, and the extent of lymph node involvement is the most important prognostic indicator. While the importance of the lymphatic system as a pathway for metastasis has been well recognized, there is very little information available about the mechanisms by which tumor cells interact with the lymphatics. Recently, production of the lymphangiogenic factor VEGF-C has been detected in tumors, and the significance of VEGF-C-mediated lymphangiogenesis for tumor metastasis has been demonstrated. Increased lymphatic vessel density has been found associated with certain tumors. The mechanisms by which tumor cells gain access to and enter lymphatic vessels are critical issues that need to be addressed in the future. In contrast to the prevailing view that has assigned to the lymphatic system a passive role in the metastatic process, our results indicate the importance of lymphatic vessel activation in tumor dissemination.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12543722     DOI: 10.1111/j.1749-6632.2002.tb04873.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  Expression of VEGFR3 in glioma endothelium correlates with tumor grade.

Authors:  S J Grau; F Trillsch; J Herms; N Thon; P J Nelson; J-C Tonn; R Goldbrunner
Journal:  J Neurooncol       Date:  2006-11-17       Impact factor: 4.130

2.  Tumor cell transendothelial passage in the absorbing lymphatic vessel of transgenic adenocarcinoma mouse prostate.

Authors:  Giacomo Azzali
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

3.  Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma.

Authors:  Kai Song; Brett H Herzog; Minjia Sheng; Jianxin Fu; J Michael McDaniel; Hong Chen; Jia Ruan; Lijun Xia
Journal:  Cancer Res       Date:  2013-10-24       Impact factor: 12.701

4.  Effect of hepatoma H22 on lymphatic endothelium in vitro.

Authors:  Hua Yu; Hong-Zhi Zhou; Chun-Mei Wang; Xiao-Ming Gu; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

5.  Expression of vascular endothelial growth factor-C and the relationship between lymphangiogenesis and lymphatic metastasis in colorectal cancer.

Authors:  Yi-Tao Jia; Zhong-Xin Li; Yu-Tong He; Wei Liang; Hui-Chai Yang; Hong-Jun Ma
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

Review 6.  Axillary surgery in breast cancer patients.

Authors:  A Millet; C A Fuster; A Lluch; F Dirbas
Journal:  Clin Transl Oncol       Date:  2007-08       Impact factor: 3.405

7.  Lymphotoxin beta receptor signaling is required for inflammatory lymphangiogenesis in the thyroid.

Authors:  Glaucia C Furtado; Tatjana Marinkovic; Andrea P Martin; Alexandre Garin; Benjamin Hoch; Wolfgang Hubner; Benjamin K Chen; Eric Genden; Mihaela Skobe; Sergio A Lira
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-14       Impact factor: 11.205

8.  Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration.

Authors:  Maria Mikhaylova; Noriko Mori; Flonné B Wildes; Piotr Walczak; Barjor Gimi; Zaver M Bhujwalla
Journal:  Neoplasia       Date:  2008-04       Impact factor: 5.715

9.  Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis.

Authors:  Chao Yan; Zheng-Gang Zhu; Ying-Yan Yu; Jun Ji; Yi Zhang; Yu-Bao Ji; Min Yan; Jun Chen; Bing-Ya Liu; Hao-Ran Yin; Yan-Zhen Lin
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

10.  Induced lymphatic sinus hyperplasia in sentinel lymph nodes by VEGF-C as the earliest premetastatic indicator.

Authors:  Ruediger Liersch; Satoshi Hirakawa; Wolfgang E Berdel; Rolf M Mesters; Michael Detmar
Journal:  Int J Oncol       Date:  2012-10-16       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.